Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Rescue Fecal Microbiota Transplantation

Research Leaders

12 sponsors active, led by St. Anna Kinderkrebsforschung

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1
Not Yet Recruiting1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05055466Completed

COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS)

NCT03895593RecruitingPrimary

Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections

NCT05121935Not Yet Recruiting

MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty

Showing all 3 trials

Research Network

Common Treatments

  • Rescue Fecal Microbiota Transplantation1

Active Sponsors

  • St. Anna Kinderkrebsforschung1
  • Haydom Lutheran Hospital1
  • The First Affiliated Hospital of Zhengzhou University1
  • Second Affiliated Hospital of Suzhou University1
  • First Affiliated Hospital of Xinjiang Medical University1

Top Investigators

Related Conditions

  • Clostridioides Difficile Infection1
  • Metabolic Syndrome1
  • Antibioticassociated Diarrhea1
  • Glucose Intolerance1
  • Growth Failure1

Activity Timeline